Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

VEGFR2-targeted contrast agent BR55

A lipopeptide-based, vascular endothelial growth factor receptor 2 (VEGRF2) -targeted contrast agent with the property of molecular imaging of angiogenesis. BR55 is prepared by incorporation of a biospecific heterodimer peptide into the perfluorobutane-containing lipid-shelled microbubble membrane; the peptide specifically binds to VEGFR2 expressed on tumoral vascular endothelium allowing ultrasound imaging of the sites of active angiogenesis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	BR55

VEGFR2-targeted contrast agent BR55

Search NCI's Drug Dictionary